OncoCyte Corp. OCX 深 沪
等待开盘 09-25 09:30:00 美东时间
3.20
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 3.20
- 总市值 9151.78万
- 52周最高 4.75
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.922
- 委 比 0.00%
- 总股本 2859.93万
- 历史最高 204.80
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.922
- 每 手 1
- 风险率 0.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多A Glimpse Into The Expert Outlook On SiTime Through 5 Analysts
SiTime (NASDAQ:SITM) has been analyzed by 5 analysts in the last three months, ...
09-19 03:01
A Glimpse Into The Expert Outlook On SiTime Through 4 Analysts
Analysts' ratings for SiTime (NASDAQ:SITM) over the last quarter vary from bull...
08-15 02:01
猎芯与川晶科技达成授权代理合作
（来源：猎芯网） 近日，国内领先的电子元器件供应链服务平台猎芯网与四川川晶科技有限公司（以下简称“川晶科技”）正式签署授权合作协议。此次合作不仅是两大行业领先企...
07-31 09:34
Deep Dive Into SiTime Stock: Analyst Perspectives (5 Ratings)
5 analysts have expressed a variety of opinions on SiTime (NASDAQ:SITM) over th...
07-19 05:00
美股大行评级 | 潜在涨幅158.9%！蒙特利尔银行上调Disc Medicine目标价至120美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1129333511617925121.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从112美元升至120美元</p> <p>• 巴克莱：维持Karyopharm Therapeutics(KPTI)"超配"评级，目标价从5美
05-14 08:48
Needham Reiterates Buy on OncoCyte, Maintains $4.25 Price Target
Needham analyst Mike Matson reiterates OncoCyte (NASDAQ:OCX) with a Buy and maintains $4.25 price target.
05-13 19:52
OncoCyte Q1 Adj. EPS $(0.19) Beats $(0.23) Estimate, Sales $2.32M Beat $154.50K Estimate
OncoCyte (NASDAQ:OCX) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.23) by 17.39 percent. This is a 83.19 percent increase over losses of $(1.13) per share from the same
05-13 04:09
Earnings Scheduled For May 12, 2025
Companies Reporting Before The Bell • Superior Industries Intl (NYSE:SUP) is pr...
05-12 16:32
美股大行评级 | 潜在涨幅686.94%！Sensei Biotherapeutics获Oppenheimer升目标价至4美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1112661771769712640.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Oppenheimer：维持Sensei Biotherapeutics(SNSE)"跑赢大市"评级，目标价从3.5美元升至4美元</p> <p>• 富国银行：上调Regulus Therapeutics(RGLS)评级至
03-29 18:13
美股大行评级 | 潜在涨幅592.64%！Larimar Therapeutics获HC Wainwright升目标价至16美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1111574370732224512.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Larimar Therapeutics(LRMR)"买入"评级，目标价从15美元升至16美元</p> <p>• HC Wainwright & Co.：维持Au
03-26 08:45
